Ik vrees ook voor morgen... (hoewel, échte vrees heb ik niet). Een correctie zou kortelings in alle geval ook te verwachten kunnen zijn omdat er nog geen echte reden voor de continu stijging is (overgewaardeerd?). Maar is eigenlijk niet zo erg want later stijgt het toch terug (jojo) àls het FDA in orde is.
Galapagos doesn't have any approved products yet. The important word in that sentence, though, is the last one. In December, Galapagos and partner Gilead Sciences (NASDAQ:GILD) filed for FDA approval of filgotinib as a treatment for rheumatoid arthritis (RA) and used a priority voucher, which will speed up the process.
Galapagos won't reap all of the rewards from filgotinib, however. The company licensed rights to the drug to Gilead in 2015, and will receive royalties starting at 20% of sales in the U.S. and in many key markets. However, Galapagos will split sales 50/50 with Gilead in several major European markets.
Gilead owns a little over 25% of Galapagos, but can't boost its stake above 29.9% during the period covered by the agreement.